Therapeutic updates and best practices in the treatment of irritable bowel syndrome with constipation (IBS-C)

Therapeutic updates and best practices in the treatment of irritable bowel syndrome with constipation (IBS-C) is organized by ScientiaCME.

Release Date: Apr 30, 2018
Expiration Date: Apr 30, 2020

Accreditation:
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE # 0574-0000-18-018-H01-P. ACPE Accreditation effective 04/30/18 expires 04/30/20. 

Description:
In this online CME self-learning program:
Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. Factors such as genetics, immune function, microbiome, psychological and environmental factors could predispose patients to develop of IBS.

Objectives:
By the end of the session the participant will be able to:
• Describe what is known about the etiology of IBS-C and its impact on patient clinical presentation
• Identify symptoms of IBS-C, describe their role in the diagnosis of the disorder, and list* any applicable lab and/or imaging studies that play a role in IBS-C diagnosis
• Evaluate treatments plans for patients with IBS-C and suggest appropriate therapies, where applicable, based on individual presentations
• Describe present and emerging drug therapies for management of IBS-C and apply them to patient cases
• Describe clinical and logistical challenges associated with treating and educating patients with IBS-C